生物技术公司Kymera Therapeutics, Inc.（股票代码：KYMR）今日盘前股价大幅下挫7.88%，引起了市场的广泛关注。
消息面上，根据美国证券交易委员会（SEC）披露的文件显示，Kymera Therapeutics的部分现有股东计划出售总计3139万股公司普通股。此类由股东发起的售股行为将增加市场中的股票供应量，通常被视为潜在的利空信号，可能引发投资者对公司股票未来走势的担忧，从而导致股价承压下跌。
需要指出的是，此次售股由公司股东发起，而非公司发行新股，因此Kymera Therapeutics公司自身不会从此次售股中获得任何收益。市场分析人士指出，大规模股东减持往往会影响市场情绪，投资者需密切关注后续市场动态及相关公告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.